These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7879206)

  • 21. Pretreatment with cyclosporin A (CyA) and anti-interleukin 2 receptor monoclonal antibody (IL-2R MAb) abrogates the anti-idiotype response in rat recipients of cardiac allografts.
    Tanaka K; Kupiec-Weglinski JW; Hancock WW; Stunkel K; Diamantstein T; Tilney NL
    Transplant Proc; 1991 Feb; 23(1 Pt 1):281-2. PubMed ID: 1990532
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of a monoclonal antibody directed against interleukin 2 receptor in recipients of kidney allografts.
    Soulillou JP; Le Mauff B; Cantarovich D; Hourmant M; Vie H; Jacques Y
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):84-6. PubMed ID: 3051598
    [No Abstract]   [Full Text] [Related]  

  • 23. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
    Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
    Transplant Proc; 1993 Feb; 25(1 Pt 1):820-2. PubMed ID: 7679844
    [No Abstract]   [Full Text] [Related]  

  • 24. Prolongation of murine cardiac allograft survival by the anti-interleukin-2 receptor monoclonal antibody AMT-13.
    Kirkman RL; Barrett LV; Koltun WA; Diamantstein T
    Transplant Proc; 1987 Feb; 19(1 Pt 1):618-9. PubMed ID: 3274828
    [No Abstract]   [Full Text] [Related]  

  • 25. Interleukin 7 receptor alpha as a potential therapeutic target in transplantation.
    Racapé M; Vanhove B; Soulillou JP; Brouard S
    Arch Immunol Ther Exp (Warsz); 2009; 57(4):253-61. PubMed ID: 19585222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of early and late activation markers on peripheral blood T lymphocytes does not reliably reflect immune events in transplanted hearts.
    Loertscher R; Forbes RD; Halabi G; Lavery P; Quinn T
    Clin Transplant; 1994 Jun; 8(3 Pt 1):230-8. PubMed ID: 8061361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
    Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
    J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
    [No Abstract]   [Full Text] [Related]  

  • 28. Early experience with anti-Tac in clinical renal transplantation.
    Kirkman RL; Shapiro ME; Carpenter CB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1766-8. PubMed ID: 2652578
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical immunosuppression, lymphocyte subsets, and host defense mechanisms.
    Guttmann RD
    Transplant Proc; 1994 Aug; 26(4):1847. PubMed ID: 8066601
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevention of heart allograft and kidney xenograft rejection by monoclonal antibody to CD45RB.
    Zhang Z; Zhong R; Jiang J; Wang J; Garcia B; Le Feuvre C; White M; Stiller C; Lazarovits A
    Transplant Proc; 1997; 29(1-2):1253. PubMed ID: 9123294
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-CD25 monoclonal antibody prevents early rejection in liver transplantation--a pilot study.
    Otto G; Thies J; Kabelitz D; Schlag H; Hofmann WJ; Herfarth C; Meuer S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1387-9. PubMed ID: 1989246
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients--CD4+ T cells play an essential role in the rejection process.
    Reinke P; Kern F; Fietze E; Döcke WD; Ewert R; Emmrich F; Volk HD
    Transplant Proc; 1995 Feb; 27(1):859-62. PubMed ID: 7879207
    [No Abstract]   [Full Text] [Related]  

  • 33. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
    Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
    Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
    [No Abstract]   [Full Text] [Related]  

  • 34. Inducible IL-2 on CD8 lymphocytes as a postoperative predictor of rejection in renal allograft recipients.
    Langley J; Dickerman R; Vergne-Marini P; Williams J; Jensik S; Kenyon N; Anderson J
    Transplant Proc; 1993 Feb; 25(1 Pt 2):939-43. PubMed ID: 8442275
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.
    Hesse CJ; van Gelder T; Vaessen LM; Knoop CJ; Balk AH; Yzermans JN; Jutte NH; Weimar W
    Immunopharmacology; 1995 Sep; 30(3):237-46. PubMed ID: 8557524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different reconstitution of peripheral blood lymphocytes and dendritic cells in liver and kidney transplant patients.
    Rondelli D; Abbasian J; Arpinati M; Panaro F; Porubsky M; Manzelli A; Oberholzer J; Benedetti E; Testa G
    Transplant Proc; 2005; 37(1):49-50. PubMed ID: 15808543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expansion of CD4+CD7- T helper cells with a TH0-TH2 function in kidney transplant recipients.
    Barrou B; Legac E; Blanc C; Bitker MO; Luciani J; Chatelain C; Debré P; Autran B
    Transplant Proc; 1995 Apr; 27(2):1676-7. PubMed ID: 7536977
    [No Abstract]   [Full Text] [Related]  

  • 40. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.